Trials / Completed
CompletedNCT04910295
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | COVID-19 vaccine | Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered. |
Timeline
- Start date
- 2021-03-26
- Primary completion
- 2022-04-30
- Completion
- 2022-12-31
- First posted
- 2021-06-02
- Last updated
- 2023-04-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04910295. Inclusion in this directory is not an endorsement.